AbbVie Deutschland GmbH & Co. KG: clinical-trial pipeline
AbbVie Deutschland GmbH & Co. KG is the sponsor of 1,458 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 237 are not yet finished and 12 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials237
Phase 2/3 and 3409
Countries69
New in 90 days12
Trials by phase
| Phase | Trials |
|---|---|
| Phase 3 | 382 |
| Not applicable | 363 |
| Phase 1 | 282 |
| Phase 2 | 247 |
| Phase 4 | 127 |
| Phase 1/2 | 30 |
| Phase 2/3 | 27 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 1,047 |
| Terminated | 133 |
| Recruiting | 111 |
| Active, not recruiting | 106 |
| Withdrawn or not authorised | 39 |
| Not yet recruiting | 20 |
| Suspended or halted | 1 |
| Unknown | 1 |
Condition areas
| Area | Trials |
|---|---|
| Immunology and rheumatology | 252 |
| Oncology | 246 |
| Ophthalmology | 235 |
| Gastroenterology and liver | 206 |
| Dermatology | 166 |
| Neurology | 129 |
| Infectious disease and vaccines | 116 |
| Cardiovascular | 106 |
| Rare and genetic diseases | 86 |
| Nephrology and urology | 56 |
| Women's health and obstetrics | 44 |
| Psychiatry and mental health | 39 |
Countries
| Country | Trials |
|---|---|
| United States | 880 |
| Canada | 320 |
| Germany | 294 |
| Spain | 283 |
| United Kingdom | 250 |
| Australia | 249 |
| France | 246 |
| Japan | 227 |
| Italy | 215 |
| Israel | 193 |
| South Korea | 188 |
| Poland | 178 |
| Belgium | 164 |
| Taiwan | 147 |
| Hungary | 139 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-19 | New trial posted | Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Qual… |
| 2026-10-13 | New trial posted | A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and On… |
| 2026-10-07 | New trial posted | A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients Wit… |
| 2026-10-05 | New trial posted | A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults |
| 2026-09-28 | New trial posted | A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofac… |
| 2026-09-22 | New trial posted | Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy A… |
| 2026-09-16 | New trial posted | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care… |
| 2026-09-10 | New trial posted | A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or A… |
| 2026-09-08 | New trial posted | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253… |
| 2026-08-31 | New trial posted | Study to Assess Participant Satisfaction After Jawline and Neck Treatment |
| 2026-08-31 | New trial posted | Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT… |
| 2026-08-28 | New trial posted | Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06100744 | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Chil… | Phase 3 | Not yet recruiting | Australia, Canada, Germany, Spain +5 |
| NCT06012240 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants… | Phase 3 | Recruiting | Argentina, Australia, Belgium, Bulgaria +23 |
| NCT06118411 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Parti… | Phase 3 | Active, not recruiting | Argentina, Belgium, Bulgaria, Canada +15 |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous… | Phase 2/3 | Active, not recruiting | Spain, France, Italy, Puerto Rico +2 |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Pa… | Phase 1 | Not yet recruiting | Germany, France, Israel, Japan +1 |
| NCT06158854 | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobul… | Phase 1/2 | Active, not recruiting | Australia, France, Greece, Italy +2 |
| NCT05753501 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in… | Phase 1 | Active, not recruiting | Canada, Germany, Spain, France +5 |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) i… | Phase 2 | Active, not recruiting | Australia, Canada, Germany, Denmark +3 |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adu… | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Canada +20 |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination… | Phase 1 | Active, not recruiting | Belgium, Bulgaria, Germany, Spain +9 |
| NCT06365853 | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Parti… | Phase 2 | Active, not recruiting | Australia, Belgium, Canada, Spain +3 |
| NCT03398135 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | Phase 3 | Active, not recruiting | Argentina, Austria, Belgium, Bulgaria +38 |
| NCT03105102 | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Bosnia & Herzegovina +43 |
| NCT06236438 | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combina… | Phase 2/3 | Active, not recruiting | Australia, Belgium, Chile, Spain +7 |
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumor… | Phase 1 | Not yet recruiting | Australia, Germany, Spain, France +7 |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With… | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Brazil +24 |
| NCT06257875 | A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) L… | Phase 2 | Not yet recruiting | Austria, Australia, Belgium, Bulgaria +27 |
| NCT06084481 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Soli… | Phase 1 | Recruiting | Australia, Spain, France, Israel +5 |
| NCT06332534 | Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately… | Phase 3 | Active, not recruiting | Australia, Belgium, Bulgaria, Brazil +14 |
| NCT06107413 | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiv… | Phase 2 | Active, not recruiting | Belgium, Germany, Spain, Israel +4 |
| NCT05527184 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | Not yet recruiting | Australia, Belgium, Canada, Germany +6 |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relap… | Phase 1 | Active, not recruiting | Australia, Germany, Israel, Italy +1 |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myelo… | Phase 1/2 | Active, not recruiting | Germany, Spain, France, United Kingdom +2 |
| NCT06461897 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous D… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Bulgaria +22 |
| NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in… | Phase 3 | Active, not recruiting | Australia, Spain, France, United Kingdom +5 |
Hiring for clinical development
AbbVie Deutschland GmbH & Co. KG has 246 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: abbvie.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "AbbVie Deutschland GmbH & Co. KG clinical trials: 237 open, 409 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/abbvie-com/, data as of 2026-10-25.